

Molecular responses in decitabine- and decitabine/venetoclax-treated patients with acute myeloid leukemia and myelodysplastic syndromes

Authors

Agata Gruszczynska,¹ Abhishek Maiti,² Christopher A. Miller,¹ Sai Mukund Ramakrishnan,¹ Daniel C. Link,¹ Geoffrey L. Uy,¹ Allegra A. Petti,³ Kala Hayes,² Courtney D. DiNardo,² Farhad Ravandi,² Timothy J. Ley,¹ David H. Spencer,⁴ Feng Gao,⁵ Marina Y. Konopleva⁶ and John S. Welch[°]

¹Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MI; ²Department of Leukemia, MD Anderson Cancer Center, Houston, TX; ³Department of Neurosurgery, Washington University School of Medicine, St. Louis, MI; ⁴Department of Pathology, Washington University School of Medicine, St. Louis, MO; ⁵Department of Surgery, Division of Public Health Sciences, Washington University School of Medicine, St. Louis, MI and ⁶Albert Einstein College of Medicine, Bronx, NY , USA

[°]*Current address: A2 Biotherapeutics, Agoura Hills, CA, USA*

Correspondence:


J.S. WELCH - jwelch@a2biotherapeutics.com

<https://doi.org/10.3324/haematol.2022.281396>

Decitabine


A.

1003-BM

Adj R2 = 0.05237 Intercept = 0.42577
Slope = -0.00083424 P = 0.12651


B.

1005-BM

Adj R2 = 1.2822e-05 Intercept = 0.19398
Slope = 0.00034841 P = 0.33051


C.

1035-BM

Adj R2 = 0.085467 Intercept = 0.092973
Slope = -0.00043757 P = 0.18487


D.

1045-BM

Adj R2 = 0.9853 Intercept = 0.39346
Slope = -0.0022727 P = 3.6827e-18


E.

1083-BM

Adj R2 = 0.8973 Intercept = 0.39867
Slope = -0.0028661 P = 1.9729e-05


F.

1108-BM

Adj R2 = 0.89484 Intercept = 0.39424
Slope = -0.006608 P = 2.1506e-20


G.

6326732-BM

Adj R2 = 0.94342 Intercept = 0.40564
Slope = -0.012937 P = 2.5564e-34


H.

6521032-BM

Adj R2 = 0.98492 Intercept = 0.39318
Slope = -0.015905 P = 1.3259e-34


I.

6523072-BM

Adj R2 = 0.96228 Intercept = 0.43298
Slope = -0.018758 P = 9.7367e-32


Decitabine/Venetoclax

A.




Red: cases with > 50% PB lymphs
MDS (N=11)
CMML (N=1)
sAML (N=6)

B.




Red: cases with > 50% PB lymphs
MDS (N=11)
CMML (N=1)
sAML (N=6)

C.




Red: cases with > 50% PB lymphs
MDS (N=11)
CMML (N=1)
sAML (N=6)


D.




E.





F.



G.







Supplemental Figure 4

Supplemental Figure 1. Representative calculations of molecular responses. A-F. Single-agent decitabine cases with stable disease. D-F. Single-agent decitabine cases with stable disease during the first 1-2 cycles followed by molecular response. G-I. Decitabine/venetoclax cases. Note responses after the first cycle.

Supplemental Figure 2. Molecular subgroup analysis. A-C. Comparison of tumor burden and molecular responses measured in BM and PB substrates from patients with MDS and sAML. D-E. Comparison of molecular responses within morphologic responses. One-way ANOVA with Dunn's multiple comparison. F-G. Comparison of molecular responses within de novo AML patients comparing CR vs. other responders (e.g. CRi/mLFS). One-way ANOVA with Dunn's multiple comparison.

Supplemental Figure 3. Clinical subgroup analysis. A-F. Impact of clinical features on overall survival within the total cohort of patients (n=95). G-H. Impact of adverse risk karyotypes within treatment cohorts. Log-rank comparisons.

Supplemental Figure 4. Subgroup analysis of overall survival based on treatment and the presence of specific gene mutations.